Results 31 to 40 of about 19,295,259 (301)

Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimeric fah-/- MiceSummary

Cellular and Molecular Gastroenterology and Hepatology, 2017
Background & Aims: Hepatitis C virus (HCV) is a leading cause of chronic liver diseases and the most common indication for liver transplantation in the United States.
Ursula Andreo, Ype P. de Jong, Margaret A. Scull, Jing W. Xiao, Koen Vercauteren, Corrine Quirk, Michiel C. Mommersteeg, Sonia Bergaya, Arjun Menon, Edward A. Fisher, Charles M. Rice   +10 more
doaj   +1 more source

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

, 1999
Hepatitis C is a global health problem caused by infection with the hepatitis C virus. Although representative prevalence data are not available from many countries, available data indicate that approximately 3% of the world's population is infected with
A.R. ZANETTI, WHO TECHNICAL CONSULTATION ON HEPATITIS C   +1 more
core   +1 more source

SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots

Emerging Microbes and Infections
SARS-CoV-2 main protease (Mpro) inhibitors are the first-line COVID-19 treatment. Nirmatrelvir is used worldwide, while ensitrelvir, licensed in Japan and Singapore, has received FDA fast-track designation.
Yuyong Zhou, Karen A. Gammeltoft, Helena D. Tjørnelund-Sjursen, Line A. Ryberg, Anna Offersgaard, Anna Czarnota, Zhe Duan, Long V. Pham, Ulrik Fahnøe, Günther H.J. Peters, Santseharay Ramirez, Jens Bukh, Judith M. Gottwein   +12 more
doaj   +1 more source

The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: A nationwide study

Journal of the Formosan Medical Association, 2021
Background/Purpose: This study aims at investigating the epidemiological profile of chronic hepatitis C (CHC) regarding hepatitis C virus (HCV) genotype in Taiwan.
Grace Hui-Min Wu, Wen-Wen Yang, Chia-Ling Liu, Raoh-Fang Pwu, Rong-Nan Chien, Po-Chang Lee, Shih-Chung Chen, Ding-Shinn Chen, Sheng-Nan Lu   +8 more
doaj   +1 more source

Risk factors for familial clustering of hepatitis C virus infection in a Chinese Han population: a cross-sectional study

BMC Public Health, 2018
Background Hepatitis C is a curable disease, but reinfection from household contact may occur in patients who have achieved sustained viral response (SVR).
Bi-fen Luo, Hui-ying Rao, Ying-hui Gao, Lai Wei   +3 more
doaj   +1 more source

The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD‐1/PD‐L1 inhibitors: A systematic review and meta‐analysis

Cancer Medicine, 2023
Background and Aim Programmed death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) inhibitors have transformed the treatment landscape of advanced hepatocellular carcinoma (HCC), but consistent responses are not observed in all patients, and prognostic ...
Yao Yang, Dongbo Chen, Bigeng Zhao, Liying Ren, Rui Huang, Bo Feng, Hongsong Chen   +6 more
doaj   +1 more source

High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor

Vaccines, 2022
Hepatitis C virus (HCV) infections pose a major public health burden due to high chronicity rates and associated morbidity and mortality. A vaccine protecting against chronic infection is not available but would be important for global control of HCV ...
Anna Offersgaard, Carlos Rene Duarte Hernandez, Anne Finne Pihl, Nandini Prabhakar Venkatesan, Henrik Krarup, Xiangliang Lin, Udo Reichl, Jens Bukh, Yvonne Genzel, Judith Margarete Gottwein   +9 more
doaj   +1 more source

MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development

Journal of Experimental & Clinical Cancer Research, 2018
Background Identification of novel MDM2 or p53 binding proteins may reveal undefined oncogenes, tumor suppressors, signaling pathways and possible treatment targets.
Xingwang Xie, Xueyan Wang, Weijia Liao, Ran Fei, Nan Wu, Xu Cong, Qian Chen, Lai Wei, Yu Wang, Hongsong Chen   +9 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Living with Hepatitis C: information for people living with Hepatitis C and their families and friends [PDF]

, 2007
Consultative Council on Hepatitis C / [200?
Consultative Council on Hepatitis C
core